Sugi Predict

Sugi Predict / Compounds / SCHEMBL554124

SCHEMBL554124

SCHEMBL554124

CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cnccn1)c1ccccc1)B1O[C@@H]2C[C@@H]3C[C@@H](C3(C)C)[C@]2(C)O1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PSMB5 P28074 18/20 0.80
▸ PSMB1 P20618 3/20 0.72
▸ PSMB2 P49721 2/20 0.67
▸ PSMB11 A5LHX3 1/20 0.65
▸ PSMD11 O00231 1/20 0.65
▸ PSMD12 O00232 1/20 0.65
▸ PSMD14 O00487 1/20 0.65
▸ PSMA7 O14818 1/20 0.65
▸ PSMD3 O43242 1/20 0.65
▸ PSMC3 P17980 1/20 0.65
▸ PSMA1 P25786 1/20 0.65
▸ PSMA2 P25787 1/20 0.65
▸ PSMA3 P25788 1/20 0.65
▸ PSMA4 P25789 1/20 0.65
▸ PSMB8 P28062 1/20 0.65
▸ PSMB9 P28065 1/20 0.65
▸ PSMA5 P28066 1/20 0.65
▸ PSMB4 P28070 1/20 0.65
▸ PSMB6 P28072 1/20 0.65
▸ PSMC2 P35998 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18024980 0.92 PSMB5 (0.82) PSMB5PSMB1PSMB2PSMB11PSMD11
SCHEMBL18024962 0.90 PSMB5 (0.84) PSMB5PSMB1PSMB2PSMB11PSMD11
SCHEMBL17059315 0.89 PSMB5 (1.00) PSMB5PSMB1PSMB2PSMB11PSMD11
SCHEMBL21652541 0.89 PSMB5 (1.00) PSMB5PSMB1PSMB2PSMB11PSMD11
SCHEMBL15590907 0.89 PSMB5 (1.00) PSMB5PSMB1PSMB2PSMB11PSMD11
SCHEMBL8098845 0.89 PSMB5 (1.00) PSMB5PSMB1PSMB2PSMB11PSMD11
SCHEMBL21974555 0.89 PSMB5 (1.00) PSMB5PSMB1PSMB2PSMB11PSMD11
SCHEMBL21532928 0.89 PSMB5 (1.00) PSMB5PSMB1PSMB2PSMB11PSMD11
SCHEMBL21652530 0.89 PSMB5 (1.00) PSMB5PSMB1PSMB2PSMB11PSMD11
SCHEMBL12517369 0.89 PSMB5 (1.00) PSMB5PSMB1PSMB2PSMB11PSMD11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9340559-B2 Proteasome inhibitor delanzomib for use in the treatment of lupus CEPHALON, INC. (US) 2016-05-17 — — US disclosed
US-8785418-B2 Lyophilization cakes of proteasome inhibitors CEPHALON, INC. (US) 2014-07-22 — — US disclosed
US-20130345174-A1 PROTEASOME INHIBITOR DELANZOMIB FOR USE IN THE TREATMENT OF LUPUS CEPHALON, INC. (US) 2013-12-26 — — US disclosed
US-8541590-B2 Proteasome inhibitors and processes for their preparation, purification and use CEPHALON, INC. (US) 2013-09-24 — — US disclosed
US-20120270840-A1 Proteasome inhibitors and processes for their preparation, purification and use CEPHALON INC. (US) 2012-10-25 — — US disclosed
US-20120035133-A1 Lyophilization Cakes of Proteasome Inhibitors CEPHALON FRANCE (FR) 2012-02-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120270840-A1 Proteasome inhibitors and processes for their preparation, purification and use PSMB1, PSMB11, PSMB7 PSMB5 6/4885PSMB1 1/4885PSMB2 11/4885
US-20130345174-A1 PROTEASOME INHIBITOR DELANZOMIB FOR USE IN THE TREATMENT OF LUPUS PSMB5, SSB, PSMB1 PSMB5 1/4885PSMB1 3/4885PSMB2 13/4885
US-20120035133-A1 Lyophilization Cakes of Proteasome Inhibitors PSMB1, PSMG3, PSMB2 PSMB5 7/4885PSMB1 1/4885PSMB2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.